Evidence of gene deletion of p21 (WAF1/CIP1), a cyclin-dependent protein kinase inhibitor, in thyroid carcinomas

British Journal of Cancer

Volumn 74, Issue 9, 1996, Pages 1336-1341

  Shi, Y ^a   Zou, M ^a   Farid, N R ^a   Al Sedairy, S T ^a  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

Author keywords

CIP1; Gene deletion; p21; RNA splicing; Thyroid neoplasm; Waf1

Indexed keywords

CYCLIN DEPENDENT KINASE; PROTEIN KINASE INHIBITOR; PROTEIN P21; PROTEIN P53;

ARTICLE; CARCINOGENESIS; CELL TRANSFORMATION; CODON; CONTROLLED STUDY; EUKARYOTIC CELL; EXON; GENE DELETION; HUMAN; HUMAN TISSUE; INTRON; MAJOR CLINICAL STUDY; POINT MUTATION; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE STRAND CONFORMATION POLYMORPHISM; SOUTHERN BLOTTING; THYROID CARCINOMA; THYROID FOLLICULAR CARCINOMA; THYROID PAPILLARY CARCINOMA;

EID: 0029800256     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.546     Document Type: Article

References (40)

1. BHATIA K, FAN S, SPANGLER G, WEINTRAUB M, O'CONNOR PM, JUDDE J-G AND MAGRATH I. (1995). A mutant p21 cyclin-dependent kinase inhibitor isolated from a Burkitt's lymphoma. Cancer Res., 55, 1431 - 1435.
2. BRAVO R, FRANK R, BLUNDELL PA AND MACDONALD-BRAVO H. (1987). Cyclin/PCNA is the auxilliary protein of DNA polymerase-δ. Nature, 326, 515 - 517.
3. CHEDID M, MICHELI P, LENGEL C, HUPPI K & GIVOL D. (1994). A single nucleotide substitution at codon 31 (Ser/Arg) defines a polymorphism in a highly conserved region of the p53-inducible gene WAF1/CIP1. Oncogene, 9, 3021 - 3024.
4. CHEN J, JACKSON PK, KIRSCHNER MW AND DUTTA A. (1995). Separate domains of p21 involved in the inhibition of Cdk kinase and PCNA. Nature, 374, 386 388.
5. DIETZ H, VALLE D, FRANCOMANO CA, KENDZIOR RJ, PYERITZ RE AND CUTTING GR. (1993). The skipping of constitutive exons in vivo induced by nonsense mutations. Science, 259, 680 683.
6. DULIC V, LEES E AND REED SR. (1992). Association of human cyclin E with a periodic G1-S phase protein kinase. Science, 257, 1958 1961.
7. EL-DEIRY WS, TOKINO T, VELCULESCU VE, LEVY DB, PARSONS R, TRENT JM, LIN D, MERCER WE, KINZLER KW AND VOGELSTEIN B. (1993). WAF1, a potential mediator of p53 tumor suppression. Cell, 75, 817 825.
8. FARID NR, SHI Y AND ZOU MJ. (1994). Molecular basis of thyroid cancer. Endocrinol. Rev., 15, 202 - 232.
9. cip1 cyclin-dependent kinase inhibitor. Oncogene, 10, 2281 - 2287.
10. GREEN MR. (1986). Pre-mRNA splicing. Annu. Rev. Genet., 20, 671 - 708.
11. HARPER JW, ADAMI GR, WEI N, KEYOMARSI K AND ELLEDGE SJ. (1993). The p21 cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell, 75, 805 - 816.
12. HERMANEK P AND SOBIN LH. (1987). TNM Classification of Malignant Tumors. pp. 33-35, Springer-Verlag: Berlin.
13. HUNTER T AND PINES J. (1994). Cyclins and cancer II: cyclin D and CDK inhibitors come of age. Cell, 79, 573 - 582.
14. HUPPI K, SIWARSKI D, DOSIK J, MICHIELI P, CHEDID M, REED S, MOCK B, GIVOL D AND MUSHINSKI JF. (1994). Molecular cloning, sequencing, chromosomal localization and expression of mouse p21 (Waf1). Oncogene, 9, 3017 - 3020.
15. JEN J, HARPER JW, BIGNER SH, BIGNER DD, PAPADOPOULOS N, MARKOWITZ S, WILLSON JKV, KINZLER KW AND VOGELSTEIN B. (1994). Deletion of p16 and p15 genes in brain tumors. Cancer Res., 54, 6353 - 6358.
16. KAMB A, GRUIS NA, WEAVER-FELDHAUS J, LIU Q, HARSHMAN K, TAVTIGIAN SV, STOCKERT E, DAY RS III, JOHNSON BE AND SKOLNICK MH. (1994). A cell cycle regulator potentially involved in the genesis of many tumor types. Science, 264, 436 - 440.
17. KOFF A, GIORDANO A, DESIA D, YAMASHITA K, HARPER JW, ELLEDGE SJ, NISHIMOTO T, MORGAN DO, FRANZA R AND ROBERTS JM. (1992). Formation and activation of cyclin E-cdk2 complex during the G1 phase of the human cell cycle. Science, 257, 1689 - 1694.
18. MATSUO M, MASUMURA T, NISHIO H, NAKAJIMA T, KITOH Y, TAKUMI T, KOGA J AND NAKAMURA H. (1991). Exon skipping during splicing of dystrophin mRNA precursor due to an intraexon deletion in the dystrophin gene of Duchenne muscular dystrophy. Kobe. J. Clin. Invest., 87, 2127 - 2131.
19. MORI T, MIURA K, AOKI T, NISHIHIRA T, MORI S AND NAKAMURA Y. (1994). Frequent somatic mutation of the MTS1/CDK4I (multiple tumor suppressor/cyclin-dependent kinase 4 inhibitor) gene in esophageal squamous cell carcinoma. Cancer Res., 54, 3396 - 3397.
20. NAMBA H, HARA T, TUKAZAKI T, MIGITA K, ISHIKAWA N, ITO K, NAGATAKI S AND YAMASHITA S. (1995). Radiation-induced G1 arrest is selectively mediated by the p53-WAF1/Cip1 pathway in human thyroid cells. Cancer Res., 55, 2075 - 2080.
21. NORBURY C AND NURSE P. (1992). Animal cell cycles and their control. Annu. Rev. Biochem., 61, 441 - 470.
22. ORITA M, IWAHANA H, KANAZAWA H, HAYASHI K AND SEKIYA T. (1989a). Detection of polymorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphisms. Proc. Natl Acad. Sci. USA, 86, 2766 - 2770.
23. ORITA M, SUZUKI Y, SEKIYA T AND HAYASHI K. (1989b). Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. Genomics, 5, 874 - 879.
24. PADGETT RA, GRABOWSKI PJ, KONARSKA MM, SEILER S AND SHARP PA. (1986). Splicing of messenger RNA precursors. Annu. Rev. Biochem., 55, 1119 - 1150.
25. PAGANO M, PEPPERKOK J, LUKAS V, BALDIN W, ANORGE J, BARTEK B AND DRAETTA G. (1993). Regulation of the human cell cycle by the cdk2 protein kinase. J. Cell Biol., 121, 101 - 111.
26. PRELICH G, KOSTURA M, MARSHAK DR, MATHEWS MB AND STILLMAN B. (1987). The cell-cycle regulated proliferating cell nuclear antigen is regulated for SV40 DNA replication in vitro. Nature, 326, 471-475.
27. SAMBROOK J, FRITSCH EF AND MANIATIS TE. (1989). Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory Press: Cold Spring Harbor, New York.
28. SCHMIDT EE, ICHIMURA K, REIFENBERGER G AND COLLINS VP. (1994). CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas. Cancer Res., 54, 6321 - 6324.
29. SHIOHARA M, EL-DEIRY WS, WADA M, NAKAMAKI T, TAKEUCHI S, YANG R, CHEN D-L, VOGELSTEIN B AND KOEFFLER HP. (1994). Absence of WAF1 mutations in a variety of human malignancies. Blood, 84, 3781 - 3784.
30. SHIVJI MKK, KENNY MK AND WOOD RD. (1992). Proliferating cell nuclear antigen is required for DNA excision repair. Cell, 69, 367 - 374.
31. WAGA S, HANNON G, BEACH D AND STILLMAN B. (1994). The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature, 369, 574 - 578.
32. WAKAMATSU N, KOBAYASHI H, MIYATAKE T AND TSUJI S. (1992). A novel exon mutation in the human β-hexosaminidase β subunit gene affects 3′ splice site selection. J. Biol. Chem., 267, 2406 - 2413.
33. XIONG Y, ZHANG H AND BEACH D. (1992). D type cyclins associate with multiple protein kinases and the DNA replication and repair factor PCNA. Cell, 71, 505 - 514.
34. XIONG Y, HANNON GJ, ZHANG H, CASSO D, KOBAYASHI R AND BEACH D. (1993). p21 is a universal inhibitor of cyclin kinases. Nature, 366, 701 - 704.
35. ZHANG H, XIONG Y AND BEACH D. (1993). Proliferating cell nuclear antigen and p21 are components of multiple cell cycle kinase complexes. Mol. Biol. Cell., 4, 897 - 906.
36. ZIELENSKI J, MARKIEWICZ D, LIN S-P, HUANG F-Y, YANG-FENG TL AND TSUI L-C. (1995). Skipping of exon 12 as a consequence of a point mutation (1898 + 5G→T) in the cystic fibrosis transmembrane conductance regulator gene found in a consanguineous Chinese family. Clin. Genet., 47, 125 - 132.
37. ZOU MJ, SHI Y AND FARID NR. (1993a). p53 mutations in all stages of thyroid carcinomas. J. Clin. Endocrinol. Metab., 77, 1054 - 1058.
38. ZOU MJ, SHI Y, AL-SEDAIRY ST AND FARID NR. (1993b). High levels of Nm23 gene expression in the advanced stage of thyroid cancer. Br. J. Cancer, 68, 385 - 388.
39. ZOU MJ, SHI Y AND FARID NR. (1994). Frequent inactivation of the retinoblastoma gene in human thyroid carcinomas. Endocrine, 2, 193 - 198.
40. ZOU MJ, SHI Y, AL-SEDAIRY ST, HUSSAIN SS AND FARID NR. (1995). The expression of the MDM2 gene, a p53 binding protein in thyroid carcinogenesis. Cancer, 76, 314 - 318.